摘要
近年来免疫检查点抑制剂(immune checkpoint inhibitors,ICI)的临床应用是肺癌治疗手段和药物发展的一个重大突破,提高了晚期肺癌患者的生存率。虽然可供选择药物和治疗模式越来越多,临床治疗也迎来了新的挑战。本文基于中国胸部肿瘤研究协作组评分(Chinese Thoracic Oncology Group,CTONG评分)系统,结合ICI药物的特性,从有效性、安全性、生存质量和补偿方面,考量药物在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)初始治疗中的临床价值,使治疗方案的制定和选择更适合免疫治疗的患者,实现最大化的生存获益。同时也为制药公司未来新药物和适应证的研究与开发提供导向。
In recent years,immune checkpoint inhibitors(ICI)have been a significant breakthrough in the treatment of lung cancer,leading to improved survival rates for patients with advanced disease.However,an increase in the number of treatment/drug options has made the choice of an appropriate treatment challenging.This article utilizes the Chinese Thoracic Oncology Group(CTONG)scoring system to assess the clinical value of ICI drugs in the initial treatment of advanced non⁃small cell lung cancer(NSCLC)in terms of efficacy,safety,quality of life,and compensation,providing reasonable guidance and optimize treatment strategies for improved patient outcomes.Moreover,the proposed score can indicate the demand for new drugs and indications.This can determine the direction of research focusing on the development of novel therapeutics and corresponding strategies for industry.
作者
刘思阳
曾康辉
揭光灵
吴一龙
LIU Si-yang Maggie;ZENG Kang-hui;JIE Guang-ling;WU Yi-long(Department of Hematology,First Affiliated Hospital,Institute of Hematology,School of Medicine,Key Laboratory for Regenerative Medicine of Ministry of Education,Ji’nan University,Guangzhou 510632,China;Guangdong Lung Cancer Institute,Guangdong Provincial People’s Hospital(Guangdong Academy of Medical Sciences),Southern Medical University,Guangzhou 510080,China)
出处
《循证医学》
2023年第2期119-124,共6页
The Journal of Evidence-Based Medicine
基金
中国博士后基金项目(2021M701422)
广东省肺癌转化医学重点实验室(2017B030314120):广东省医学领军人才配套科研项目(KJ012019426)。
